Pediatric antifungal therapy. Part II: Neonatal infections

U. D. Allen, S. Richardson, W. McGuire, E. Bow, J. Robinson, C. Rotstein, J. Doyle, D. Davies, C. Hui, N. Le Saux, P. Merchant, M. Laverdiere, S. Read

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.

Original languageEnglish (US)
Pages (from-to)71-78
Number of pages8
JournalMinerva Pediatrica
Issue number1
StatePublished - Feb 2010
Externally publishedYes


  • Antifungal agents
  • Candidiasis
  • Infant, newborn
  • Mycoses

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Pediatric antifungal therapy. Part II: Neonatal infections'. Together they form a unique fingerprint.

Cite this